(1) Using cutting-edge adjuvant systems “L-pampo™” with activating TLR2 and TLR3 to induce Th1 immune response.
(2) Phase I study was done with CVI-HBV-002 in S. Korea in early 2024.
(3) Promising efficacy with rapid seroprotection with 100% protection after the two doses.
(4) Promising safety with no serious adverse events occurring.
(5) Had a Pre-IND meeting with US FDA in Q4 2024.
(6) Global Phase II study planned in Q3 2025.
(7) Open for out-licensing or co-development and investment in WW.